Sanitas AB announces that Valeant Pharmaceuticals International, Inc. (“Valeant”) yesterday, 9th June 2011, submitted an application to the Antimonopoly Committee of Ukraine for clearance of the proposed transaction. This application has also been made in connection with Valeant’s intended acquisition of the 87.2% shareholding in Sanitas AB from the funds advised by Citi Venture Capital International (“CVCI”, through the legal entities Citigroup Venture Capital International Jersey Limited and Baltic Pharma Limited), Invalda AB (“Invalda”), Amber Trust II S.C.A. (“Amber”) and certain other persons (together the “Controlling Shareholders”). A further announcement will be made when appropriate.
This announcement is also available on Sanitas’ website: www.sanitasgroup.com.